Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.

Lugaresi A, di Ioia M, Travaglini D, Pietrolongo E, Pucci E, Onofrj M.

Neuropsychiatr Dis Treat. 2013;9:893-914. doi: 10.2147/NDT.S45144. Epub 2013 Jun 24.

2.

Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).

Jongen PJ, Hengstman G, Hupperts R, Schrijver H, Gilhuis J, Vliegen JH, Hoogervorst E, van Huizen M, van Munster E, Samijn J, de Schryver E, Siepman T, Tonk M, Zandbergen E, ten Holter J, van der Kruijk R, Borm G.

BMC Neurol. 2011 Mar 30;11:40. doi: 10.1186/1471-2377-11-40.

3.

Natalizumab for relapsing remitting multiple sclerosis.

Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007621. doi: 10.1002/14651858.CD007621.pub2. Review.

PMID:
21975773
4.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
5.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
6.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
7.

First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Johnston J, So TY.

Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000. Review.

PMID:
22642799
8.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
9.

Dietary interventions for multiple sclerosis.

Farinotti M, Vacchi L, Simi S, Di Pietrantonj C, Brait L, Filippini G.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD004192. doi: 10.1002/14651858.CD004192.pub3. Review.

PMID:
23235605
10.

[Immunomodulatory therapy in multiple sclerosis].

Csépány T, Bereczki D.

Ideggyogy Sz. 2004 Nov 20;57(11-12):401-16. Review. Hungarian.

PMID:
15662768
11.

Interferons and natalizumab for multiple sclerosis.

Clar C, Velasco Garrido M, Gericke C, Busse R.

GMS Health Technol Assess. 2008 Oct 1;4:Doc09.

12.

Recommendations for diagnosis and management of multiple sclerosis.

Kes VB, Zavoreo I, Serić V, Solter VV, Cesarik M, Hajnsek S, Pasić MB, Gabelić T, Silvio B, Butković SS, Lusić I, Grbelja LD, Vladić A, Bielen I, Antoncić I, Demarin V; Croatian Society for Neurovascular Disorders of Croatian Medical Association; Croatian Society of Neurology of Croatian Medical Association; Referral Center for Demyelinating Diseases of the CNS.

Acta Clin Croat. 2012 Mar;51(1):117-35.

PMID:
22920014
13.

Treatment of multiple sclerosis.

Anlar O.

CNS Neurol Disord Drug Targets. 2009 Jun;8(3):167-74. Review.

PMID:
19601814
14.

Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.

Johnson KP.

Expert Rev Neurother. 2012 Apr;12(4):371-84. doi: 10.1586/ern.12.25. Review.

PMID:
22449210
15.

Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents.

Girouard N, Soucy N.

Patient Prefer Adherence. 2011 Feb 27;5:101-8. doi: 10.2147/PPA.S10506.

16.

Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.

Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS.

Health Technol Assess. 2005 May;9(21):1-179, iii-iv. Review.

17.

Prescribing recommendations for interferon-Beta in multiple sclerosis.

Weinstock-Guttman B, Rudick RA.

CNS Drugs. 1997 Aug;8(2):102-12. doi: 10.2165/00023210-199708020-00002.

PMID:
23338215
18.

Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence.

Bayas A, Mäurer M.

Patient Prefer Adherence. 2015 Feb 9;9:265-74. doi: 10.2147/PPA.S61651. eCollection 2015. Review.

19.

Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod.

Gasperini C, Ruggieri S, Mancinelli CR, Pozzilli C.

Ther Clin Risk Manag. 2013;9:73-85. doi: 10.2147/TCRM.S17426. Epub 2013 Mar 3.

20.

Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges.

Fontoura P.

MAbs. 2010 Nov-Dec;2(6):670-81. doi: 10.4161/mabs.2.6.13270. Review.

Items per page

Supplemental Content

Write to the Help Desk